sharonyeo的个人主页 - 老虎社区

sharonyeo

暂无个人介绍

IP属地：未知

15关注

2粉丝

0主题

0勋章

2021-12-01

Like

A GE Bear Drops the Hammer Again. Why the Split Won’t Work.

2021-11-26

Hi

Roche shareholders approve deal to buy Novartis's $20.7 billion stake

2021-11-24

Good...

抱歉，原内容已删除

2021-11-24

Ok

抱歉，原内容已删除

2021-11-24

Buy..more

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4099878636929790","uuid":"4099878636929790","gmtCreate":1636780389540,"gmtModify":1636780389540,"name":"sharonyeo","pinyin":"sharonyeo","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":15,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":603311442,"gmtCreate":1638365336291,"gmtModify":1638365336447,"author":{"id":"4099878636929790","authorId":"4099878636929790","name":"sharonyeo","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099878636929790","authorIdStr":"4099878636929790"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603311442","repostId":"1193294379","repostType":4,"repost":{"id":"1193294379","kind":"news","pubTimestamp":1638360110,"share":"https://www.laohu8.com/m/news/1193294379?lang=&edition=full","pubTime":"2021-12-01 20:01","market":"us","language":"en","title":"A GE Bear Drops the Hammer Again. Why the Split Won’t Work.","url":"https://stock-news.laohu8.com/highlight/detail?id=1193294379","media":"Barrons","summary":"JPMorgan analyst Stephen Tusa doesn’t see a breakup improving General Electric’s fortunes—and he’s m","content":"<p>JPMorgan analyst Stephen Tusa doesn’t see a breakup improving General Electric’s fortunes—and he’s making his case again. Others on Wall Street, though, are more upbeat.</p>\n<p>General Electric&nbsp;(ticker:GE) is splitting&nbsp;into three businesses: aerospace, healthcare, and power generation. CEO Larry Culp believes more parts is the best way to generate shareholder value.</p>\n<p>Big breakups can be risky.DowDuPont&nbsp;shareholders holding shares of&nbsp;Dow&nbsp;(DOW),DuPont de Nemours&nbsp;(DD), and&nbsp;Corteva&nbsp;(CTVA) have lagged behind the market. But United Technology shareholders have beaten the market if they hung onto shares of&nbsp;Raytheon Technologies&nbsp;(RTX),Carrier Global&nbsp;(CARR), and&nbsp;Otis Worldwide&nbsp;(OTIS).</p>\n<p>The GE split is a part of the long turnaround being led by Culp. He took over in 2018 and has sold assets to pay down about $80 billion in debt.</p>\n<p>But Tusa isn’t giving Culp credit for the breakup plan. “The answer for this time is different is mostly around management,” Tusa wrote in a note Tuesday. “The plan today is far from original, essentially the same as former CEO Flannery had in store.”</p>\n<p>Culp took over for John Flannery, who succeeded Jeffery Immelt. GE has struggles since late in Immelt’s tenure. Stock in GE was north of $200 about a month before he left in mid-2017.</p>\n<p>Tusa also questions the $20-plus billion sale of GE biopharma to&nbsp;Danaher&nbsp;(DHR), which came early in Culp’s tenure. He thinks GE left tens of billions of dollars are the table. GE did need to raise cash, in part to fund insurance liabilities that stretched back years. It wasn’t a good time for the company.</p>\n<p>GE declined to comment on the analyst’s note.</p>\n<p>Tusa is about as bearish on GE as anyone on Wall Street. Tuesday’s note is one of several he has written panning the breakup. He rates share Neutral, which essentially means he believes they will keep up with the market, but his price target is a Street-low $55 a share.</p>\n<p>JPMorgan uses Underweight, Neutral, and Overweight ratings instead of Sell, Buy, and Hold. JPMorgan declined to comment on maintaining a Neutral rating with a target price far below where the stock trades.</p>\n<p>Others on Wall Street just don’t agree with Tusa. Bank of America analyst Andrew Obin wrote a research report Tuesday after an investor call he hosted for bank clients with GE management.</p>\n<p>“Our call focused on big picture changes at GE,” wrote Obin. He believes Culp is splitting up the company to bring operation focus to each business. “Investor feedback was broadly positive, but lacking conviction.”</p>\n<p>Investors might be nervous, but Obin remains bullish, rating shares Buy. His price target is $140. UBS analyst Markus Mittermaier is another GE bull. He rates share Buy and has a $143 price target.</p>\n<p>On Monday, Mittermaier wrote that the “triplet” companies will have a simpler capital structure going forward. Business simplification along with less debt are two reasons he remains bullish.</p>\n<p>Overall, 65% of analysts covering GE rate shares Buy. The average Buy-rating ratio for stocks in the&nbsp;S&amp;P 500&nbsp;is about 55%.</p>\n<p>GE stock seems to have most of the Street with it. Investors, like Obin points out, aren’t quite there yet. GE stock is down about 10% since announcing its breakup not quite a month ago. The S&amp;P 500 and&nbsp;Dow Jones Industrial Average&nbsp;are off about 1% and 4%, respectively, over the same span.</p>\n<p>The spins will take a while—not wrapping up until 2024. That’s a long time to wait and one reason investors might have sold stock. That long time is also a reason the bull bear debate will rage for months longer.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A GE Bear Drops the Hammer Again. Why the Split Won’t Work.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA GE Bear Drops the Hammer Again. Why the Split Won’t Work.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 20:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/a-ge-bear-drops-the-hammer-again-why-the-split-wont-work-51638293882?mod=hp_DAY_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JPMorgan analyst Stephen Tusa doesn’t see a breakup improving General Electric’s fortunes—and he’s making his case again. Others on Wall Street, though, are more upbeat.\nGeneral Electric (ticker:GE) ...</p>\n\n<a href=\"https://www.barrons.com/articles/a-ge-bear-drops-the-hammer-again-why-the-split-wont-work-51638293882?mod=hp_DAY_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GE":"GE航空航天"},"source_url":"https://www.barrons.com/articles/a-ge-bear-drops-the-hammer-again-why-the-split-wont-work-51638293882?mod=hp_DAY_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193294379","content_text":"JPMorgan analyst Stephen Tusa doesn’t see a breakup improving General Electric’s fortunes—and he’s making his case again. Others on Wall Street, though, are more upbeat.\nGeneral Electric (ticker:GE) is splitting into three businesses: aerospace, healthcare, and power generation. CEO Larry Culp believes more parts is the best way to generate shareholder value.\nBig breakups can be risky.DowDuPont shareholders holding shares of Dow (DOW),DuPont de Nemours (DD), and Corteva (CTVA) have lagged behind the market. But United Technology shareholders have beaten the market if they hung onto shares of Raytheon Technologies (RTX),Carrier Global (CARR), and Otis Worldwide (OTIS).\nThe GE split is a part of the long turnaround being led by Culp. He took over in 2018 and has sold assets to pay down about $80 billion in debt.\nBut Tusa isn’t giving Culp credit for the breakup plan. “The answer for this time is different is mostly around management,” Tusa wrote in a note Tuesday. “The plan today is far from original, essentially the same as former CEO Flannery had in store.”\nCulp took over for John Flannery, who succeeded Jeffery Immelt. GE has struggles since late in Immelt’s tenure. Stock in GE was north of $200 about a month before he left in mid-2017.\nTusa also questions the $20-plus billion sale of GE biopharma to Danaher (DHR), which came early in Culp’s tenure. He thinks GE left tens of billions of dollars are the table. GE did need to raise cash, in part to fund insurance liabilities that stretched back years. It wasn’t a good time for the company.\nGE declined to comment on the analyst’s note.\nTusa is about as bearish on GE as anyone on Wall Street. Tuesday’s note is one of several he has written panning the breakup. He rates share Neutral, which essentially means he believes they will keep up with the market, but his price target is a Street-low $55 a share.\nJPMorgan uses Underweight, Neutral, and Overweight ratings instead of Sell, Buy, and Hold. JPMorgan declined to comment on maintaining a Neutral rating with a target price far below where the stock trades.\nOthers on Wall Street just don’t agree with Tusa. Bank of America analyst Andrew Obin wrote a research report Tuesday after an investor call he hosted for bank clients with GE management.\n“Our call focused on big picture changes at GE,” wrote Obin. He believes Culp is splitting up the company to bring operation focus to each business. “Investor feedback was broadly positive, but lacking conviction.”\nInvestors might be nervous, but Obin remains bullish, rating shares Buy. His price target is $140. UBS analyst Markus Mittermaier is another GE bull. He rates share Buy and has a $143 price target.\nOn Monday, Mittermaier wrote that the “triplet” companies will have a simpler capital structure going forward. Business simplification along with less debt are two reasons he remains bullish.\nOverall, 65% of analysts covering GE rate shares Buy. The average Buy-rating ratio for stocks in the S&P 500 is about 55%.\nGE stock seems to have most of the Street with it. Investors, like Obin points out, aren’t quite there yet. GE stock is down about 10% since announcing its breakup not quite a month ago. The S&P 500 and Dow Jones Industrial Average are off about 1% and 4%, respectively, over the same span.\nThe spins will take a while—not wrapping up until 2024. That’s a long time to wait and one reason investors might have sold stock. That long time is also a reason the bull bear debate will rage for months longer.","news_type":1,"symbols_score_info":{"GE":0.9}},"isVote":1,"tweetType":1,"viewCount":1303,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877205404,"gmtCreate":1637932173981,"gmtModify":1637932207028,"author":{"id":"4099878636929790","authorId":"4099878636929790","name":"sharonyeo","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099878636929790","authorIdStr":"4099878636929790"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877205404","repostId":"1190474385","repostType":4,"repost":{"id":"1190474385","kind":"news","pubTimestamp":1637924231,"share":"https://www.laohu8.com/m/news/1190474385?lang=&edition=full","pubTime":"2021-11-26 18:57","market":"us","language":"en","title":"Roche shareholders approve deal to buy Novartis's $20.7 billion stake","url":"https://stock-news.laohu8.com/highlight/detail?id=1190474385","media":"Reuters","summary":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion de","content":"<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.</p>\n<p>Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.</p>\n<p>Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.</p>\n<p>They also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.</p>\n<p>Therefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.</p>\n<p>\"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"</p>\n<p>Novartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.</p>\n<p>The repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.</p>\n<p>Novartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.</p>\n<p>Roche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche shareholders approve deal to buy Novartis's $20.7 billion stake</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche shareholders approve deal to buy Novartis's $20.7 billion stake\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 18:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an ...</p>\n\n<a href=\"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RHHBY":"罗氏控股","NVS":"诺华"},"source_url":"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190474385","content_text":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.\nShareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.\nThey also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.\nTherefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.\n\"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"\nNovartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.\nThe repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.\nNovartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.\nRoche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.","news_type":1,"symbols_score_info":{"NVS":0.9,"RHHBY":0.9}},"isVote":1,"tweetType":1,"viewCount":1415,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874122161,"gmtCreate":1637746176822,"gmtModify":1637746176934,"author":{"id":"4099878636929790","authorId":"4099878636929790","name":"sharonyeo","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099878636929790","authorIdStr":"4099878636929790"},"themes":[],"htmlText":"Good...","listText":"Good...","text":"Good...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874122161","repostId":"2185911330","repostType":4,"isVote":1,"tweetType":1,"viewCount":3080,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874126279,"gmtCreate":1637746118519,"gmtModify":1637746118647,"author":{"id":"4099878636929790","authorId":"4099878636929790","name":"sharonyeo","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099878636929790","authorIdStr":"4099878636929790"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874126279","repostId":"2185920330","repostType":4,"isVote":1,"tweetType":1,"viewCount":1553,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874126317,"gmtCreate":1637746077407,"gmtModify":1637746116009,"author":{"id":"4099878636929790","authorId":"4099878636929790","name":"sharonyeo","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099878636929790","authorIdStr":"4099878636929790"},"themes":[],"htmlText":"Buy..more","listText":"Buy..more","text":"Buy..more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874126317","repostId":"1190583301","repostType":4,"isVote":1,"tweetType":1,"viewCount":1736,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":603311442,"gmtCreate":1638365336291,"gmtModify":1638365336447,"author":{"id":"4099878636929790","authorId":"4099878636929790","name":"sharonyeo","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099878636929790","authorIdStr":"4099878636929790"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603311442","repostId":"1193294379","repostType":4,"repost":{"id":"1193294379","kind":"news","pubTimestamp":1638360110,"share":"https://www.laohu8.com/m/news/1193294379?lang=&edition=full","pubTime":"2021-12-01 20:01","market":"us","language":"en","title":"A GE Bear Drops the Hammer Again. Why the Split Won’t Work.","url":"https://stock-news.laohu8.com/highlight/detail?id=1193294379","media":"Barrons","summary":"JPMorgan analyst Stephen Tusa doesn’t see a breakup improving General Electric’s fortunes—and he’s m","content":"<p>JPMorgan analyst Stephen Tusa doesn’t see a breakup improving General Electric’s fortunes—and he’s making his case again. Others on Wall Street, though, are more upbeat.</p>\n<p>General Electric&nbsp;(ticker:GE) is splitting&nbsp;into three businesses: aerospace, healthcare, and power generation. CEO Larry Culp believes more parts is the best way to generate shareholder value.</p>\n<p>Big breakups can be risky.DowDuPont&nbsp;shareholders holding shares of&nbsp;Dow&nbsp;(DOW),DuPont de Nemours&nbsp;(DD), and&nbsp;Corteva&nbsp;(CTVA) have lagged behind the market. But United Technology shareholders have beaten the market if they hung onto shares of&nbsp;Raytheon Technologies&nbsp;(RTX),Carrier Global&nbsp;(CARR), and&nbsp;Otis Worldwide&nbsp;(OTIS).</p>\n<p>The GE split is a part of the long turnaround being led by Culp. He took over in 2018 and has sold assets to pay down about $80 billion in debt.</p>\n<p>But Tusa isn’t giving Culp credit for the breakup plan. “The answer for this time is different is mostly around management,” Tusa wrote in a note Tuesday. “The plan today is far from original, essentially the same as former CEO Flannery had in store.”</p>\n<p>Culp took over for John Flannery, who succeeded Jeffery Immelt. GE has struggles since late in Immelt’s tenure. Stock in GE was north of $200 about a month before he left in mid-2017.</p>\n<p>Tusa also questions the $20-plus billion sale of GE biopharma to&nbsp;Danaher&nbsp;(DHR), which came early in Culp’s tenure. He thinks GE left tens of billions of dollars are the table. GE did need to raise cash, in part to fund insurance liabilities that stretched back years. It wasn’t a good time for the company.</p>\n<p>GE declined to comment on the analyst’s note.</p>\n<p>Tusa is about as bearish on GE as anyone on Wall Street. Tuesday’s note is one of several he has written panning the breakup. He rates share Neutral, which essentially means he believes they will keep up with the market, but his price target is a Street-low $55 a share.</p>\n<p>JPMorgan uses Underweight, Neutral, and Overweight ratings instead of Sell, Buy, and Hold. JPMorgan declined to comment on maintaining a Neutral rating with a target price far below where the stock trades.</p>\n<p>Others on Wall Street just don’t agree with Tusa. Bank of America analyst Andrew Obin wrote a research report Tuesday after an investor call he hosted for bank clients with GE management.</p>\n<p>“Our call focused on big picture changes at GE,” wrote Obin. He believes Culp is splitting up the company to bring operation focus to each business. “Investor feedback was broadly positive, but lacking conviction.”</p>\n<p>Investors might be nervous, but Obin remains bullish, rating shares Buy. His price target is $140. UBS analyst Markus Mittermaier is another GE bull. He rates share Buy and has a $143 price target.</p>\n<p>On Monday, Mittermaier wrote that the “triplet” companies will have a simpler capital structure going forward. Business simplification along with less debt are two reasons he remains bullish.</p>\n<p>Overall, 65% of analysts covering GE rate shares Buy. The average Buy-rating ratio for stocks in the&nbsp;S&amp;P 500&nbsp;is about 55%.</p>\n<p>GE stock seems to have most of the Street with it. Investors, like Obin points out, aren’t quite there yet. GE stock is down about 10% since announcing its breakup not quite a month ago. The S&amp;P 500 and&nbsp;Dow Jones Industrial Average&nbsp;are off about 1% and 4%, respectively, over the same span.</p>\n<p>The spins will take a while—not wrapping up until 2024. That’s a long time to wait and one reason investors might have sold stock. That long time is also a reason the bull bear debate will rage for months longer.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A GE Bear Drops the Hammer Again. Why the Split Won’t Work.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA GE Bear Drops the Hammer Again. Why the Split Won’t Work.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 20:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/a-ge-bear-drops-the-hammer-again-why-the-split-wont-work-51638293882?mod=hp_DAY_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JPMorgan analyst Stephen Tusa doesn’t see a breakup improving General Electric’s fortunes—and he’s making his case again. Others on Wall Street, though, are more upbeat.\nGeneral Electric (ticker:GE) ...</p>\n\n<a href=\"https://www.barrons.com/articles/a-ge-bear-drops-the-hammer-again-why-the-split-wont-work-51638293882?mod=hp_DAY_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GE":"GE航空航天"},"source_url":"https://www.barrons.com/articles/a-ge-bear-drops-the-hammer-again-why-the-split-wont-work-51638293882?mod=hp_DAY_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193294379","content_text":"JPMorgan analyst Stephen Tusa doesn’t see a breakup improving General Electric’s fortunes—and he’s making his case again. Others on Wall Street, though, are more upbeat.\nGeneral Electric (ticker:GE) is splitting into three businesses: aerospace, healthcare, and power generation. CEO Larry Culp believes more parts is the best way to generate shareholder value.\nBig breakups can be risky.DowDuPont shareholders holding shares of Dow (DOW),DuPont de Nemours (DD), and Corteva (CTVA) have lagged behind the market. But United Technology shareholders have beaten the market if they hung onto shares of Raytheon Technologies (RTX),Carrier Global (CARR), and Otis Worldwide (OTIS).\nThe GE split is a part of the long turnaround being led by Culp. He took over in 2018 and has sold assets to pay down about $80 billion in debt.\nBut Tusa isn’t giving Culp credit for the breakup plan. “The answer for this time is different is mostly around management,” Tusa wrote in a note Tuesday. “The plan today is far from original, essentially the same as former CEO Flannery had in store.”\nCulp took over for John Flannery, who succeeded Jeffery Immelt. GE has struggles since late in Immelt’s tenure. Stock in GE was north of $200 about a month before he left in mid-2017.\nTusa also questions the $20-plus billion sale of GE biopharma to Danaher (DHR), which came early in Culp’s tenure. He thinks GE left tens of billions of dollars are the table. GE did need to raise cash, in part to fund insurance liabilities that stretched back years. It wasn’t a good time for the company.\nGE declined to comment on the analyst’s note.\nTusa is about as bearish on GE as anyone on Wall Street. Tuesday’s note is one of several he has written panning the breakup. He rates share Neutral, which essentially means he believes they will keep up with the market, but his price target is a Street-low $55 a share.\nJPMorgan uses Underweight, Neutral, and Overweight ratings instead of Sell, Buy, and Hold. JPMorgan declined to comment on maintaining a Neutral rating with a target price far below where the stock trades.\nOthers on Wall Street just don’t agree with Tusa. Bank of America analyst Andrew Obin wrote a research report Tuesday after an investor call he hosted for bank clients with GE management.\n“Our call focused on big picture changes at GE,” wrote Obin. He believes Culp is splitting up the company to bring operation focus to each business. “Investor feedback was broadly positive, but lacking conviction.”\nInvestors might be nervous, but Obin remains bullish, rating shares Buy. His price target is $140. UBS analyst Markus Mittermaier is another GE bull. He rates share Buy and has a $143 price target.\nOn Monday, Mittermaier wrote that the “triplet” companies will have a simpler capital structure going forward. Business simplification along with less debt are two reasons he remains bullish.\nOverall, 65% of analysts covering GE rate shares Buy. The average Buy-rating ratio for stocks in the S&P 500 is about 55%.\nGE stock seems to have most of the Street with it. Investors, like Obin points out, aren’t quite there yet. GE stock is down about 10% since announcing its breakup not quite a month ago. The S&P 500 and Dow Jones Industrial Average are off about 1% and 4%, respectively, over the same span.\nThe spins will take a while—not wrapping up until 2024. That’s a long time to wait and one reason investors might have sold stock. That long time is also a reason the bull bear debate will rage for months longer.","news_type":1,"symbols_score_info":{"GE":0.9}},"isVote":1,"tweetType":1,"viewCount":1303,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877205404,"gmtCreate":1637932173981,"gmtModify":1637932207028,"author":{"id":"4099878636929790","authorId":"4099878636929790","name":"sharonyeo","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099878636929790","authorIdStr":"4099878636929790"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877205404","repostId":"1190474385","repostType":4,"repost":{"id":"1190474385","kind":"news","pubTimestamp":1637924231,"share":"https://www.laohu8.com/m/news/1190474385?lang=&edition=full","pubTime":"2021-11-26 18:57","market":"us","language":"en","title":"Roche shareholders approve deal to buy Novartis's $20.7 billion stake","url":"https://stock-news.laohu8.com/highlight/detail?id=1190474385","media":"Reuters","summary":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion de","content":"<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.</p>\n<p>Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.</p>\n<p>Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.</p>\n<p>They also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.</p>\n<p>Therefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.</p>\n<p>\"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"</p>\n<p>Novartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.</p>\n<p>The repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.</p>\n<p>Novartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.</p>\n<p>Roche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.</p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche shareholders approve deal to buy Novartis's $20.7 billion stake</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche shareholders approve deal to buy Novartis's $20.7 billion stake\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-26 18:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an ...</p>\n\n<a href=\"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RHHBY":"罗氏控股","NVS":"诺华"},"source_url":"https://finance.yahoo.com/news/roche-shareholders-approve-deal-buy-101846094.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190474385","content_text":"ZURICH (Reuters) - Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.\nRoche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades.\nShareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.\nThey also backed the plan to cancel the 53.3 million shares bought, with a majority of 99.85%.\nTherefore, the corporate law requirements for the repurchase have been satisfied, Roche said. The closing of the repurchase transaction is expected to take place in early December 2021.\n\"Today's resolutions of the Extraordinary General Meeting are in the best economic and strategic interest of Roche,\" said Roche Chairman Christoph Franz. \"As a result, we will be even better positioned to make a contribution to the health of people around the world.\"\nNovartis agreed earlier this month to sell 53.3 million Roche bearer shares for $388.99 (356.93 Swiss francs) per share, a price that reflected the volume-weighted average of the Roche non-voting equity certificates over the 20 trading days to Nov. 2.\nThe repurchase was conditional upon the approval by shareholders of a capital reduction by cancellation of the repurchased shares and of the interim financial statements prepared for the transaction.\nNovartis' involvement started in 2001, when Swiss activist investor Martin Ebner, known for orchestrating the merger that created banking giant UBS, offered his Roche stake to its cross-town rival out of frustration over rebuffed proposals.\nRoche Chairman Franz said earlier this month that the deal would give his company more strategic flexibility, as Roche could now make plans without needing the approval of Novartis.","news_type":1,"symbols_score_info":{"NVS":0.9,"RHHBY":0.9}},"isVote":1,"tweetType":1,"viewCount":1415,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874122161,"gmtCreate":1637746176822,"gmtModify":1637746176934,"author":{"id":"4099878636929790","authorId":"4099878636929790","name":"sharonyeo","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099878636929790","authorIdStr":"4099878636929790"},"themes":[],"htmlText":"Good...","listText":"Good...","text":"Good...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874122161","repostId":"2185911330","repostType":4,"isVote":1,"tweetType":1,"viewCount":3080,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874126279,"gmtCreate":1637746118519,"gmtModify":1637746118647,"author":{"id":"4099878636929790","authorId":"4099878636929790","name":"sharonyeo","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099878636929790","authorIdStr":"4099878636929790"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874126279","repostId":"2185920330","repostType":4,"isVote":1,"tweetType":1,"viewCount":1553,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874126317,"gmtCreate":1637746077407,"gmtModify":1637746116009,"author":{"id":"4099878636929790","authorId":"4099878636929790","name":"sharonyeo","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099878636929790","authorIdStr":"4099878636929790"},"themes":[],"htmlText":"Buy..more","listText":"Buy..more","text":"Buy..more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874126317","repostId":"1190583301","repostType":4,"isVote":1,"tweetType":1,"viewCount":1736,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}